Storage of polyvinylpyrrolidone (PVP) in tissues following long-term treatment with a PVP-containing vasopressin preparation.
The parenteral use of polyvinylpyrrolidone (PVP) leads to PVP retention in the human organism. Four case histories dealing with patients on long-term treatment with a PVP-containing vasopressin preparation are presented and the possibility of a harmful effect of the PVP storage is discussed. The presence of PVP in serum, demonstrated by lipoprotein electrophoresis, is described. Based on the literature and the present findings, a withdrawal of PVP-containing preparations for injectional purposes is advocated.
D000328:Adult; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011205:Povidone / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D013997:Time Factors; D014018:Tissue Distribution; D014667:Vasopressins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D014667:Vasopressins; D011205:Povidone